Lumira invests in BAROnova USD$36.5M Series D financing
BAROnova, Inc., has closed a Series D financing of USD$36.5 million.
Delos Capital led the round and Longitude Capital co-led the round, with participation from existing investors Lumira Capital Partners, ONSET Ventures and Sante Ventures.
BAROnova® will use the proceeds to fund the U.S. pivotal study of the TransPyloric Shuttle® (TPS®), BAROnova’s novel endoscopically delivered and retrieved weight-loss device.
The U.S. Food and Drug Administration recently granted BAROnova an unconditional approval to initiate the U.S. pivotal clinical investigation of the TPS, known as the ENDObesity® II Study, which will be used to support a Premarket Approval Application (PMA) with the FDA.
The first subject is expected to be enrolled before the end of 2015.